This CPB has been revised to remove the requirement for a baclofen infusion pump that persons must be monitored closely in a fully equipped and staffed environment during the screening phase and dosage-titration period immediately following the implant. This CPB is revised to state that baclofen infusion pumps are considered experimental and investigational for chronic neuropathic pain.